Omalizumab – Asian Pacific Journal of Allergy and Immunology

August 9, 2026

Drug persistence of omalizumab, cyclosporine,and hydroxychloroquinein antihistamine-refractory chronic spontaneous urticaria: A biomarker-stratified real-world study

Real-world comparative data on alternatives to omalizumab for antihistamine-refractory chronic spontaneous urticaria (CSU) are limited, particularly in resource-constrained Asia-Pacific settings.

autoimmune markers, biomarkers, chronic spontaneous urticaria, cyclosporine, drug survival, Hydroxychloroquine, Omalizumab, total IgE, treatment persistence

November 2, 2021

Severe allergic asthma: Does alexithymia interfere with omalizumab treatment outcome?

Alexithymia is among psychological factors reported to interfere with asthma management. Severe allergic asthma (SAA) is characterized by uncontrolled asthma despite maximal standard pharmacological treatment which can benefit from an add-on treatment with Omalizumab, an anti-IgE monoclonal antibody.

alexithymia, Allergy, Asthma, Omalizumab, Quality of life

January 30, 2021

Depression scores change significantly after omalizumab treatment in patients with chronic spontaneous urticaria

Chronic spontaneous urticaria (CSU) is frequently associated with psychiatric comorbidities.

biomarker, depression, Omalizumab, psychiatric comorbidity, urticaria

January 30, 2021

Efficacy of drug therapies in antihistamine refractory chronic spontaneous urticaria: Real life data

Omalizumab is a safe and effective treatment for antihistamine-refractory chronic spontaneous urticaria (CSU) but is insufficient in one-third of patients. For serious cases in which omalizumab is ineffective, cyclosporine or methotrexate may be preferred. Most drug trials in CSU have focused on omalizumab or cyclosporine monotherapy.

chronic spontaneous urticaria, cyclosporine, efficacy, methotrexate, Omalizumab, safety, treatment

March 16, 2020

Efficacy and safety of omalizumab in patients with moderate-to-severe asthma: An analytic comparison of data from randomized controlled trials between Chinese and Caucasians

Omalizumab has > 15 years of real-world evidence of effectiveness in Caucasian patients. In August 2017, it was approved as an add-on therapy for the management of moderate-to-severe asthma in China.

Asthma, Caucasian, Chinese, comparative analysis, Omalizumab